Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Systematic review of pharmacological treatments in fragile X syndrome.

Rueda JR, Ballesteros J, Tejada MI.

BMC Neurol. 2009 Oct 13;9:53. doi: 10.1186/1471-2377-9-53. Review.

2.

Folic acid for fragile X syndrome.

Rueda JR, Ballesteros J, Guillen V, Tejada MI, Solà I.

Cochrane Database Syst Rev. 2011 May 11;(5):CD008476. doi: 10.1002/14651858.CD008476.pub2. Review.

PMID:
21563169
3.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

4.

Chemoprevention of colorectal cancer: systematic review and economic evaluation.

Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D, Tappenden P.

Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320. Review.

5.

[Methylphenidate in the treatment of attention-deficit/hyperactivity disorder: are we achieving an adequate clinical practice?].

Gonzalez de Dios J, Cardó E, Servera M.

Rev Neurol. 2006 Dec 16-31;43(12):705-14. Review. Spanish.

6.

Evidence based evaluation of immuno-coagulatory interventions in critical care.

Afshari A.

Dan Med Bull. 2011 Sep;58(9):B4316. Review.

PMID:
21893014
7.

Treatments for fragile X syndrome: a closer look at the data.

Hall SS.

Dev Disabil Res Rev. 2009;15(4):353-60. doi: 10.1002/ddrr.78. Review.

9.
10.

Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Tsiouris JA, Brown WT.

CNS Drugs. 2004;18(11):687-703. Review.

PMID:
15330685
11.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
12.

[Review of psychopharmacological treatments in adolescents and adults with autistic disorders].

Baghdadli A, Gonnier V, Aussilloux C.

Encephale. 2002 May-Jun;28(3 Pt 1):248-54. Review. French.

PMID:
12091786
14.

Potential pharmacological treatment of fragile X syndrome during adulthood.

Xu ZH, Zhao MG.

Neurosci Bull. 2009 Oct;25(5):296-300. doi: 10.1007/s12264-009-0909-0. Review.

PMID:
19784085
15.

CX-516 Cortex pharmaceuticals.

Danysz W.

Curr Opin Investig Drugs. 2002 Jul;3(7):1081-8. Review.

PMID:
12186271
16.

Emerging pharmacologic treatment options for fragile X syndrome.

Schaefer TL, Davenport MH, Erickson CA.

Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. Review.

17.

Benefits of Physical Exercise for Individuals with Fragile X Syndrome in Humans.

Lee M, Won J, Lee S, Hong Y, Kim JH, Hong Y.

J Lifestyle Med. 2015 Sep;5(2):35-8. doi: 10.15280/jlm.2015.5.2.35. Review.

Items per page

Supplemental Content

Support Center